<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210524051384N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-08-24</date_registration>
      <primary_sponsor>Deputy of Research and Technology, Guilan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effects of biological (amniotic) with traditional dressings in the treatment of deep second degree burn wounds 5-20% in less than 24 hours in patients admitted to the Velayat hospital</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effects of biological (amniotic) with traditional dressings in the treatment of deep second degree burn wounds 5-20% in less than 24 hours in patients admitted to the Velayat hospital</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>42</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58057</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Blocking and allocation sequences will be done by the person not involved in the research to hide the patient's choice. The sample allocation ratio will be (1: 1) and will be divided into control and intervention groups. Then, based on the obtained blocks and in the order of allocation, the dressings will be placed on the patients of the control and intervention groups. In this study, blinding will not occur due to the different appearance of biological (amniotic) and traditional dressings. In this study, to assign patients to intervention and control groups, the limited randomization approach will be used in parallel with the block randomization method. We will consider random blocks of size 4.
A table of random numbers (Random allocation software ) will be used to generate random numbers.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Acute burn.</hc_freetext>
      <i_freetext>Intervention 1: biological dressing: For patients with grade 2 burns, in group A, after cleaning the burned surface and removing blisters and foreign objects from the burn site, washing with normal saline will be performed, and then biological dressing (amniotic fluid) will be served. The amniotic biological dressing is prepared from a pair of healthy mothers after a selective cesarean section at Al-Zahra Hospital. According to health protocols for mothers, blood samples are sent to the laboratory for testing for HCV, HBS, and HIV. The embryonic-related layers of the placenta are separated under the hood and then washed under sterile conditions with Ringer's solution. The amniotic layer is separated and transferred to cold sterilized containers (4 ° C). to remove the blood and other contaminants, it will be washed four times with normal saline. Once with 0.25% sodium hypochlorite solution, and washed again with normal saline. Then, the samples are transferred to sterile containers and refrigerated. When placing the amniotic membrane, care should be taken; that the underlying layers, which can reproduce, should be placed on the wound. Intervention 2: B) Traditional dressings: In group B, dressings will be applied in a traditional and daily manner according to the protocol of the Velayat hospital. After washing the wound with normal saline and debridement if necessary, ointments  (Flamazine, Adiazine ،Mafenaide, Sulfamylon) are applied to the wound and then with plain gas. Will be covered and dressed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is I haven't decided yet - the release schedule is still unknown</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ammirmohammad Gholipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Velayat Hospital, Namjoo St, Rasht, Guilan, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193713191</zip>
        <telephone>+98 13 3336 8860</telephone>
        <email>Velayathospital@gmail.com</email>
        <affiliation>Guilan University Of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Mohammadreza Mobayen</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Namjoo St, Velayat Hospital,  Rasht, Guilan, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193713191</zip>
        <telephone>+98 13 3336 8860</telephone>
        <email>Maziar.mobayen@gmail.com</email>
        <affiliation>Guilan university of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18 to 60 years
Grade 2 burns
Burns that are greater than 20 to 25 percent
Admission less than 24 hours from the occurrence of burns
Thermal burns with boiling water or flammable substances
No underlying diseases such as diabetes, immune system deficiency, connective tissue disease, kidney disease, liver disease and hepatitis, etc.
Satisfaction of participating in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Age over 60 years
Patients who died during the study
Dissatisfaction with continuing the study
Impossibility to follow the patient treatment process</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T30</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Burn and Corrosion, Body Region Unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>biological dressing: For patients with grade 2 burns, in group A, after cleaning the burned surface and removing blisters and foreign objects from the burn site, washing with normal saline will be performed, and then biological dressing (amniotic fluid) will be served. The amniotic biological dressing is prepared from a pair of healthy mothers after a selective cesarean section at Al-Zahra Hospital. According to health protocols for mothers, blood samples are sent to the laboratory for testing for HCV, HBS, and HIV. The embryonic-related layers of the placenta are separated under the hood and then washed under sterile conditions with Ringer's solution. The amniotic layer is separated and transferred to cold sterilized containers (4 ° C). to remove the blood and other contaminants, it will be washed four times with normal saline. Once with 0.25% sodium hypochlorite solution, and washed again with normal saline. Then, the samples are transferred to sterile containers and refrigerated. When placing the amniotic membrane, care should be taken; that the underlying layers, which can reproduce, should be placed on the wound.</i_keyword>
      <i_keyword>B) Traditional dressings: In group B, dressings will be applied in a traditional and daily manner according to the protocol of the Velayat hospital. After washing the wound with normal saline and debridement if necessary, ointments  (Flamazine, Adiazine ،Mafenaide, Sulfamylon) are applied to the wound and then with plain gas. Will be covered and dressed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Average recovery time. Timepoint: daily. Method of measurement: Based on disease course / percentage.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice-Chancellor for Research, Guilan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-07-28</approval_date>
        <contact_name>Research Ethics Committees Of Guilan University Of Medical Sciences</contact_name>
        <contact_address>Guilan University Of Medical Science Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
